FDA Warns Altru Telehealth Over "Our Compounding Pharmacies Are All FDA Approved" and Related GLP-1 Claims
On June 8, 2026, FDA issued a warning letter to Altru Telehealth after a March 2026 review of altrutelehealth.com, which offers compounded semaglutide and tirzepatide products. FDA cites claims such as "Compounded semaglutide & tirzepatide offers the same results but at a fraction of the cost of brand names such as Ozempic, Mounjaro & Wegovy" and "[o]ur compounding pharmacies are all FDA approved," which FDA calls "false and misleading" because compounded drugs and compounding pharmacies are not FDA-approved. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
Source: FDA original ↗